Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized hypertonic saline with or without hyaluronic acid in stable COPD with viscous sputum
ACTRN12626000461392Phase 4Recruiting
- Sponsor
- Bogomolets National Medical University
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sodium chloride, sodium hyaluronate and acetylcysteine in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Bogomolets National Medical University. Primary endpoints: Change in cough severity from baseline to day 10, Change in sputum expectoration from baseline to day 10 and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
sodium chloridesodium hyaluronateacetylcysteine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12626000461392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000461392.